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Aim: This study evaluates the acute toxicity outcome in patients treated with RapidArc for
localized prostate cancer.
Background: Modern technologies allow the delivery of high doses to the prostate while
lowering the dose to the neighbouring organs at risk. Whether this dosimetric advantage
translates into clinical beneﬁt is not well known.
Materials and methods: Between December 2009 and May 2012, 45 patients with primary
prostate adenocarcinoma were treated using RapidArc. All patients received 1.8 Gy per frac-
tion, the median dose to the prostate gland, seminal vesicles, pelvic lymph nodes and
surgical bed was 80 Gy (range, 77.4–81 Gy), 50.4 Gy, 50.4 Gy and 77.4 Gy (range, 75.6–79.2 Gy),
respectively.
Results: The time between the last session and the last treatment follow up was a median
of  10 months (range, 3–24 months). The incidence of grade 3 acute gastrointestinal (GI) and
genitourinary (GU) toxicity was 2.2% and 15.5%, respectively. Grade 2 acute GI and GU toxicity
occurred in 30% and 27% of patients, respectively. No grade 4 acute GI and GU toxicity were
observed. Older patients (>median) or patients with V60 higher than 35% had signiﬁcantly
higher rates of grade ≥2 acute GI toxicity compared with the younger ones.
Conclusions: RapidArc in the treatment of localized prostate cancer is tolerated well with noGrade >3 GI and GU toxicities. Older patients or patients with higher V60 had signiﬁcantly
higher rates of grade ≥2 acute GI toxicity. Further research is necessary to assess deﬁnitive
late toxicity and tumour control outcome.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All∗ Corresponding author. Tel.: +502 2311 0400; fax: +502 2311 0400.
E-mail address: ralere03@hotmail.com.ar (R.E. Lengua).
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analysis criteria (DD = 3%, DTA = 2 mm,  (<1) 94%). The average
dose volume histograms for the PTV, bladder and rectum can
been seen in Figs. 1–2.
Table 1 – Patient characteristics.
Characteristic No. of patients (%)
Age (years)
Median (range) 67 (43–81)
Gleason
<7 2 (4)
7 21 (47)
>7 12 (48)
T stage
T1 10 (22)
T2 16 (36)
T3 18 (40)
T4 1 (2)
PSA (ng/ml)
<10 27 (60)
10–19 9 (20)
>20 9 (20)
Risk
Low 2 (4)
Intermediate 11 (24)
High 32 (72)
Androgen deprivation
No 12 (48)
Yes 33 (52)
Radiation dose (Gy)
Median (range) 80 (77.4–81)
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.  Background
rostate Cancer is one of the most frequent tumours in men
round the world. In the United States of America, prostate
ancer is the number one non coetaneous cancer in men, and
t is the second most common in Europe.1 The American Can-
er Society estimates that in 2013 there will be 238,590 new
ases diagnosed of prostate cancer in the United States and
9,720 men  will die for it.2
External beam radiotherapy (EBRT) is a standard treatment
odality for localized and locally advanced prostate cancer.3,4
he practice of primary EBRT for prostate cancer has changed
ramatically over the past years. Modern technologies allow
he delivery of high doses to the prostate while lowering the
ose to the neighbouring organs at risk.5,6 Escalation of the
adiation dose beyond 70 Gy has improved biochemical con-
rol in low, intermediate and high risk patients, but the rates
f rectal toxicity also increased. Volumetric modulated arc
herapy using RapidArc is a novel modality of radiotherapy
elivery that allows the radiation dose to be delivered dur-
ng gantry rotation. This technology improves dose conformity
hile signiﬁcantly shortening treatment time; it delivers treat-
ents two to eight times faster than other treatments. It has
een made possible by a treatment planning algorithm that
imultaneously changes three parameters during treatment:
otation speed of the gantry, shape of the treatment aperture
sing the movement  of multileaf collimator leaves in both
irections and delivery dose rate.7
However, even with IMRT,  up to 50% of the patients treated
ith doses >70 Gy experience bladder of bowel symptoms dur-
ng treatment.8 Clinical variables such as any pretreatment
ymptoms, androgen suppression, and prior transurethral
esection of the prostate appeared to be important progno-
tic factors for radiation induced acute genitourinary (GU) and
astrointestinal (GI) toxicity.5 The use of modern radiation
echnology is needed to avoid excessive toxicity technology
s needed to avoid excessive toxicity with higher doses, as has
een shown in randomized trials.9
.  Aim
he purpose of this study was to evaluate the acute toxic-
ty outcome in patients treated with RapidArc for localized
rostate cancer, with the hypothesis that using RapidArc it is
ossible to reach local control by giving a standard dose to the
arget volume without increasing the risk of injury or toxicity
n the organs at risk in patients with localized disease.
.  Materials  and  methods
.1.  Selection  criteria
etween December 2009 and May 2012, 45 patients were
reated for primary prostate cancer. Inclusion criteria were
rimary diagnosis of adenocarcinoma of the prostate (T1c-
4)10 and no prior history of radiotherapy. All patients were
tratiﬁed by risk groups, based upon the current National
omprehensive Centre Network prognostic risk groupings,therapy 1 9 ( 2 0 1 4 ) 234–238 235
which include the low risk, intermediate risk and high risk.11
Pretreatment evaluation consisted of documented history and
physical examination, including performance status, digital
rectal examination and serum prostate speciﬁc antigen (PSA)
values performed. Base line patient characteristics are shown
in Table 1.
3.2.  Treatment
All patients were treated using a Clinac iX, equipped with
Millenium Multileaf Colimator (MLC120), On Board Imager,
and RapidArc capabilities. Patients were immobilized in the
supine position with the same immobilization device comb-
iﬁx and instructions were given regarding daily preparation,
full bladder (instructed to drink a glass of water 30 min  before
treatment). The planning target volume (PTV) was deﬁned by
5–10 mm margin from the prostate or surgical bed.
All the treatment plans consisted in two complete arcs,
with 177 control points each. Optimization for the PTV, blad-
der, rectum femoral heads, penile bulb and bowels was done
using Eclipse V8.6 (Varian Medical Systems) optimizator and
the Analytical Anisotropic Algorithm (AAA) for dose calcula-
tion. Dose constraints used in the plan prescription are shown
in Table 2. All treatment plans were veriﬁed by quality assur-
ance process before treating the patient, using the gammaNo 3 (7)
Yes 42 (93)
Prostate planning tumour volume (cc)
Median (range) 95 (27–245)
236  reports of practical oncology and rad
Table 2 – Dose constraints used in the plan prescription.
Organ Doseconstraint
Small bowel (individual loops) V15 <120cc
Small bowel (peritoneal cavity) V45 <195cc
Rectum V50 <50%
Rectum V60 <35%
Rectum V65 <25%
Rectum V70 <20%
Rectum V75 <15%
Bladder V60 <50%
Bladder V70 <35%
Bladder V75 <25%
Bladder V80 <15%
(RTOG) scoring system. Secondary endpoints were biochem-
ical failure-free survival deﬁned by the American Society for
Therapeutic Radiology and Oncology (ASTRO) and the PhoenixFifteen patients received treatment to the surgical bed. All
patients received 1.8 Gy per fraction, the median dose to the
prostate gland, seminal vesicles, pelvic lymph nodes and sur-
gical bed was 80 Gy (range, 77.4–81 Gy), 50.4 Gy, 50.4 Gy and
77.4 Gy (range, 75.6–79.2 Gy), respectively. The prescribed dose
covered at least 95% of the PTV and the common organ at risk
dose constraints were used.12Fig. 1 – An example of a dose volume histogram for the pelvic ly
irradiation.
Fig. 2 – An example of a dose volume histograiotherapy 1 9 ( 2 0 1 4 ) 234–238
3.3.  Patient  care
All patients during the course of radiotherapy were seen
every Monday (weekly) and more  often if needed for clini-
cal evaluation and disease management. After completion of
the therapy, we evaluated every patient at approximately two
weeks and then every 3 months. The evaluations consisted of a
history and physical examination. Serum PSA values were per-
formed every three months for the ﬁrst year after treatment,
every 4 months for the second year, and every 6 months for
the following years. Any additional studies were obtained at
the discretion of the treating physician.
3.4.  Statistical  methods
All data analyses were done using the SPSS (version 19.0) sta-
tistical software. The primary endpoint was the occurrence
of any grade ≥2 acute GU and GI toxicity within 3 months
of RT, scored using the Radiation Therapy Oncology Group
13(nadir + 2) deﬁnition, including any clinical failure deﬁned as
mph nodes (50.4 Gy) and the planning tumour (81 Gy)
m for the (A) rectum and the (B) bladder.
reports of practical oncology and radio
Table 3 – Acute complications for all patients according
Radiation Therapy Oncology Group scale.
Acute
genitourinary
toxicity
Acute
gastrointestinal
toxicity
No patients (%) No patients (%)
Grade 0 15 (33) 8 (17)
Grade 1 15 (33) 18 (40)
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toxicity. Another important fact not taken into consider-Grade 2 14 (31) 12 (27)
Grade 3 1 (2) 7 (15)
ocal, regional, or distant relapse. Potential risk factors for tox-
city were assessed in a univariate logistic regression analysis.
ecause of the possible confounding effect of clinical factors
n toxicity, associations found to be signiﬁcant in the univari-
te analysis were adjusted by patient (age), tumour (diagnosis
SA, gleason, T stage, N stage, risk, planning tumour volume
PTV]),10 treatment (indication [deﬁnitive, adjuvant, salvage],
reatment time, radiation dose, pelvic lymph nodes treat-
ent), and dosimetric factors. Multivariate Cox regression was
erformed to adjust for factors signiﬁcant on univariate anal-
sis, as well as any other factors that might have confounded
he univariate analysis. Quantitative variables were evaluated
y using the median as the cut-off.
.  Results
he median age at diagnosis was 65 (range, 43–81 years)
nd the median follow up was 10 months (range, 0–24
onths). Four patients had biochemical recurrence, two cases
ith bone metastasis conﬁrmed by images and two cases
nknown.
.1.  Toxicity  data
he incidence of grade 3 acute gastrointestinal and genitouri-
ary toxicity was 2% (n = 1) and 15% (n = 7), respectively. Grade
 and 2 acute gastrointestinal toxicity occurred in 31.1% (n = 15)
nd 30% (n = 14), respectively. Grade 1 and 2 acute genitouri-
ary toxicity occurred in 18 and 12 patients, respectively. No
rade 4 acute GI and GU toxicity were observed (Table 3).
.2.  Prognostic  factorseveral factors including dosimetric parameters were evalu-
ted as predictors of acute toxicity in a univariate analysis
see statistical subsection). In the multivariate analysis, older
Table 4 – Multivariate analysis of factors signiﬁcantly associate
Variable Acute gastrointestinal toxicity
OR 9
Age (years)
≤median 1.0
≥median 4.2 1
Rectum V60 (%)
≤median 1.0
≥median 4.9 1therapy 1 9 ( 2 0 1 4 ) 234–238 237
patients (>median) had signiﬁcantly higher rates of grade ≥2
acute GI toxicity compared with the younger ones (P = 0.03). In
addition, the rectum V60 showed a signiﬁcant association with
grade ≥2 acute GI toxicity in the univariate and multivariate
analyses (P = 0.02 and P = 0.02, respectively; Table 4). Patients
treated with a higher rectum V60 (>median) had signiﬁcantly
higher rates of grade ≥2 acute GI toxicity compared with those
treated with a lower rectum V60. Median V60 was 12% (range,
2.4–38). No other factor was independently associated with
acute GI and GU toxicity.
5.  Discussion
This is the ﬁrst study in Guatemala that reports toxicity of
prostate cancer using a modern RT technology (RapidArc) for
treatment. The purpose of this study was to evaluate the tox-
icity outcome in patients treated with RapidArc for localized
prostate cancer, with the hypothesis that using RapidArc it is
possible to reach local control by giving a standard dose to the
target volume without increasing the risk of injury or toxic-
ity in the organs at risk in patients with localized disease. In
our study, older patients (>median) had signiﬁcantly higher
rates of grade ≥2 acute GI toxicity compared with the younger
ones (P = 0.003). In addition, the rectum V60 showed a signiﬁ-
cant association with grade ≥2 acute GI toxicity (P = 0.02). No
other factor was independently associated with acute GU or
GU toxicity.
Most recent studies have reported that patients treated
with RapidArc less frequently experienced acute toxicities and
trended towards less GU toxicities as compared with patients
treated with other techniques. Decreased acute toxicity for
patients treated with modulated RT is likely a function of
both enhanced daily imaging technology and visceral wall
sparing.14–18
Aizer et al. reported that patients with larger prostates
(>50cc) were more  likely to develop genitourinary toxicity, an
association that remained signiﬁcant after multivariate analy-
sis (P = 0.006).19 Patients with larger prostates should therefore
be aware about the increased risk of incurring such toxicity
when undergoing External Beam Radiotherapy for prostate
cancer, particularly if other studies conﬁrm the relationship
among prostate size, bladder dose, and acute genitourinary
20ation was bladder ﬁlling. Jain et al. reported that bladder ﬁlling
appeared to be a dominant factor which predicted for acute
toxicity following the use of IMRT.21
d with ≥2 grade 2 acute gastrointestinal toxicity.
 grade ≤2
5% CI P value
.1–15.4 0.03
.3–19.1 0.02
d rad
r
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1
1
1
1
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Mark et al. reported that men  treated with RT to an intact
prostate had signiﬁcant grade ≥2 acute toxicity in contrast
to men  treated with post-prostatectomy RT to similar dose
with a greater percentage of bladder in-ﬁeld due to surgical
repositioning, but there was no difference in late toxicity.22
These ﬁndings suggest that acute urinary toxicity may be due
to RT-related inﬂammation of the prostate and prostatic ure-
thra, and not RT injury to the bladder. Despite having modern
technology, other factors may inﬂuence patient response to
therapy.
We acknowledge several limitations of our study. First, the
study is a retrospective single-centre experience of a small and
heterogeneous (i.e. deﬁnitive vs. adjuvant treatment) group of
prostate patients who  had been treated with RapidArc, rather
than being treated prospectively on a well-deﬁned treatment
protocol; the follow-up is still short, hence the long-term
efﬁcacy and toxicity are yet to be determined. Second, we  rec-
ognize that factors such as the radiation dose as well as the
percentage of bladder/rectum irradiated may have inﬂuenced
the onset of acute toxicity.
We conclude that, although the follow-up time is relatively
short, clinical outcome of Rapid in prostate cancer reducing
rectum and bladder dose have so far been successful. GI and
GU toxicities were tolerable without any grade >3 side effect.
In addition, older patients or patients with higher V60 had
signiﬁcantly higher rates of grade ≥2 acute GI toxicity. Fur-
ther research is necessary to assess deﬁnitive late toxicity and
tumour control outcome.
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